Baseline characteristics and crude incidence rate of lymphomas among biologic-naïve, TNFi, rituximab, tocilizumab or abatacept-treated patients with RA
| Bionaïve | TNFi | Rituximab | Tocilizumab | Abatacept | Total | |
| No. of patients | 71 088 | 47 864* | 9094 | 2029 | 1708* | 124 997* |
| Follow-up time (pyrs) | 322 167 | 242 260* | 29 810 | 2827 | 3352* | 584 236* |
| Female (%) | 72.1 | 74.8 | 79.0 | 80.1 | 78.0 | 73.7 |
| Age mean (mean range) | 61.1 (57–62) | 55.0 (50–57) | 57.9 (58–58) | 55.9 (55–57) | 57.5 (56–58) | 58.5 (50–62) |
| No. of lymphomas | 288 | 230 | 6 | 6 | 3 | 533 |
| Incidence per 100 000 pyrs (95% CI) | 89 (79–100) | 81 (70–94) | 20 (7–44) | 177 (57–413) | 60 (7–216) | 85 (77–92) |
*Because of the type of the register these data are missing from RATIO and GISEA, 38 incident TNFi-exposed lymphoma cases (RATIO: 27, GISEA: 11) and one abatacept-exposed patient (GISEA) were for that reason excluded from the calculation of the incidence rate.
GISEA, Italian Group for the Study of Early Arthritis; pyrs, patient-years; RA, rheumatoid arthritis; RATIO, French Research Axed on Tolerance of bIOtherapies; TNFi, tumour necrosis factor inhibitor.